You're reading the free version. Trader adds the live tape and alerts.
Start tracking
ELVN Sale Disclosure
Collins Helen Louise · SEC Form 4 · Filed Jul 21, 2026
Sale
Calculated transaction value
$116.67K
Collins Helen Louise Chief Medical Officer
ELVN
Enliven Therapeutics
ELVN
Transaction date
Jul 17, 2026
Public filing date
Jul 21, 2026
Filing lag
Filed 4 days later
ELVN daily price context
Close on/before transaction
$53.2
Jul 17, 2026
First close after public filing
$52.85
Jul 22, 2026
30-day return after filing
+11.49%
Through Aug 20, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 2,184 shares @ $53.42
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001701247-26-000011
Filing cohort
Transactions in this filing
Showing 7 of 7
Trades
7
Issuers
1
Estimated value
$275.77K
Buys / sales
0 / 5
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Enliven Therapeutics, Inc. ELVN | Exercise | Jul 17, 2026 | $12.4K |
| Enliven Therapeutics, Inc. ELVN | Sale | Jul 17, 2026 | $11.56K |
| Enliven Therapeutics, Inc. ELVN | Sale | Jul 17, 2026 | $23.66K |
| Enliven Therapeutics, Inc. ELVN Current | Sale | Jul 17, 2026 | $116.67K |
| Enliven Therapeutics, Inc. ELVN | Sale | Jul 17, 2026 | $3.4K |
| Enliven Therapeutics, Inc. ELVN | Exercise | Jul 17, 2026 | $0 |
| Enliven Therapeutics, Inc. ELVN | Sale | Jul 17, 2026 | $108.08K |